We have shown that compound 1 lowers CSC, CD44+CD24+, and CD44− subpopulations and expression of CD15s in CD44+CD24+ and CD44− cells, showing that it or similar analogs could be developed into new treatments for triple-negative breast cancer. This evidence concerns the gene CD44 and triple-negative breast carcinoma.